RESUMEN
Objective: To provide supports for the cancer prevention and control strategies in China by comparing the disease burden, epidemic trends, 5-year relative survival rate and major determinants of common cancers between China and the United States. Methods: A descriptive secondary analysis was conducted using data extracted from the GLOBOCAN database, the Surveillance, Epidemiology, and End Results database, Global Burden of disease 2019 database, and previous studies. The main indicators included the cases of malignant tumors in different sites, the cases of deaths, the age-standardized incidence (world standard incidence) and mortality (world standard mortality), the 5-year relative survival rate, and population attributable fraction (PAF). Results: In 2022, an estimated 4.825 million new cases and 2.574 million deaths of malignant neoplasms in China. The world standard incidence rate (201.6/100 000) in China was lower than that in the United States (367.0/100 000), and the world standard mortality rate (96.5/100 000) was higher than that in the United States (82.3/100 000). Lung cancer ranked first in the disease burden of malignant tumors in China, the new cases and deaths accounted for 22.0% and 28.5% of all malignant tumors, respectively. The top three malignant tumors in China were breast cancer (11.5%), prostate cancer (9.7%) and lung cancer (9.5%), which were also among the top five causes of death. However, the second to fifth leading causes of death from malignant tumors in China were digestive system tumors (liver cancer 12.3%, stomach cancer 10.1%, colorectal cancer 9.3%, and esophageal cancer 7.3%). From 2000 to 2018, the world standard incidence of malignant tumors showed an increasing trend and the world standard mortality of malignant tumors showed a decreasing trend in China, while the world standard incidence and mortality of malignant tumors in the United States showed a significant decreasing trend after 2000. The incidence of breast cancer, colorectal cancer and thyroid cancer increased rapidly in China, while the incidence and mortality of stomach cancer, liver cancer and esophageal cancer decreased, but they still had a heavy disease burden. From 2003 to 2015, the overall 5-year relative survival rate of malignant tumors increased from 30.9% to 40.5% in China. However, with the exception of esophageal cancer, the 5-year relative survival rates of other major malignant tumors were lower than those in the United States. In 2019, the PAF of malignant tumors death attributable to potential modifiable risk factors was 48.3% in China, which was similar to the United States (49.8%). Of these, smoking was the most important attributable risk factor, and the PAF was more than 30% both in China and the United States. In addition, about 18.8% of malignant tumors were caused by preventable chronic infections, such as hepatitis B virus and Helicobacter pylori, while less than 4% of malignant tumors in the United States were caused by infection. Conclusions: China has made great progress in the prevention and treatment of malignant tumors, but it still faces a serious disease burden. The cancer spectrum is changing from developing countries to developed countries. We should pay attention to modifiable factors, take comprehensive measures, and prevent cancer scientifically.
Asunto(s)
Neoplasias , Humanos , China/epidemiología , Estados Unidos/epidemiología , Neoplasias/epidemiología , Incidencia , Factores de Riesgo , Tasa de Supervivencia , Femenino , Masculino , Prevalencia , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/mortalidad , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/mortalidad , Bases de Datos Factuales , Neoplasias de la Próstata/epidemiología , Neoplasias Esofágicas/epidemiología , Neoplasias Esofágicas/mortalidad , Neoplasias del Sistema Digestivo/epidemiología , Neoplasias Colorrectales/epidemiología , Neoplasias Hepáticas/epidemiología , Neoplasias de la Tiroides/epidemiologíaRESUMEN
Objective: To determine the total and age-specific cut-off values of total prostate specific antigen (tPSA) and the ratio of free PSA divided total PSA (fPSA/tPSA) for screening prostate cancer in China. Methods: Based on the Chinese Colorectal, Breast, Lung, Liver, and Stomach cancer Screening Trial (C-BLAST) and the Tianjin Common Cancer Case Cohort (TJ4C), males who were not diagnosed with any cancers at baseline since 2017 and received both tPSA and fPSA testes were selected. Based on Cox regression, the overall and age-specific (ï¼60, 60-ï¼70, and ≥70 years) accuracy and optimal cut-off values of tPSA and fPSA/tPSA ratio for screening prostate cancer were evaluated with time-dependent receiver operating characteristic curve (tdROC) and area under curve (AUC). Bootstrap resampling was used to internally validate the stability of the optimal cut-off value, and the PLCO study was used to externally validate the accuracy under different cut-off values. Results: A total of 5 180 participants were included in the study, and after a median follow-up of 1.48 years, a total of 332 prostate cancer patients were included. In the total population, the tdAUC of tPSA and fPSA/tPSA screening for prostate cancer were 0.852 and 0.748, respectively, with the optimal cut-off values of 5.08 ng/ml and 0.173, respectively. After age stratification, the age specific cut-off values of tPSA in the <60, 60-<70, and ≥70 age groups were 3.13, 4.82, and 11.54 ng/ml, respectively, while the age-specific cut-off values of fPSA/tPSA were 0.153, 0.135, and 0.130, respectively. Under the age-specific cut-off values, the sensitivities of tPSA screening for prostate cancer in males <60, 60-70, and ≥70 years old were 92.3%, 82.0%, and 77.6%, respectively, while the specificities were 84.7%, 81.3%, and 75.4%, respectively. The age-specific sensitivities of fPSA/tPSA for screening prostate cancer were 74.4%, 53.3%, and 55.9%, respectively, while the specificities were 83.8%, 83.7%, and 83.7%, respectively. Both bootstrap's internal validation and PLCO external validation provided similar results. The combination of tPSA and fPSA/tPSA could further improve the accuracy of screening. Conclusion: To improve the screening effects, it is recommended that age-specific cut-off values of tPSA and fPSA/tPSA should be used to screen for prostate cancer in the general risk population.
Asunto(s)
Detección Precoz del Cáncer , Antígeno Prostático Específico , Neoplasias de la Próstata , Humanos , Masculino , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/sangre , Antígeno Prostático Específico/sangre , Anciano , Persona de Mediana Edad , Detección Precoz del Cáncer/métodos , Factores de Edad , Curva ROC , China , Sensibilidad y Especificidad , Tamizaje Masivo/métodos , Área Bajo la CurvaRESUMEN
Thyroid nodules are extremely common. Ultrasonography is the most effective imaging modality to diagnose and differentiate thyroid nodules. There are many versions of thyroid image reporting and data system(TI-RADS) evaluated by ultrasound, but some classification system indexes are complicated and clinical application is chaotic. In 2017, the American College of Radiology (ACR) published white papers that introduced a TI-RADS classification system based on conventional ultrasound to reduce the dependence on operators and facilitate communication with physicians. The purpose of the ACR TI-RADS is to establish the risk classification system for managing thyroid nodules and guide the physicians to make professional judgments. The ACR TI-RADS risk classification system is interpreted in this article, including the development, overview and feature categories of ACR TI-RADS, and authors' experiences in clinical application.
Asunto(s)
Nódulo Tiroideo/clasificación , Nódulo Tiroideo/diagnóstico por imagen , Ultrasonografía , Sistemas de Datos , Humanos , Guías de Práctica Clínica como Asunto , Radiología , Sociedades Médicas , Estados UnidosRESUMEN
Adult mites' bodies of Dermatophagoides farinae were used as antigen in an indirect fluorescent antibody test (IFAT) to detect mite-specific IgG in sera of 48 patients with intestinal acariasis based on stool examination. Antibody titers with positive reaction ranged from 1:4 to 1:512 in 48 patients with intestinal acariasis. If antibody titers > or = 1:16 is regarded as being positive, the positive rate of patients detected with IFAT was 92%.
Asunto(s)
Parasitosis Intestinales/diagnóstico , Infestaciones por Ácaros/diagnóstico , Animales , Estudios de Casos y Controles , Heces/parasitología , Femenino , Técnica del Anticuerpo Fluorescente Indirecta/métodos , Humanos , Masculino , Ácaros/clasificaciónRESUMEN
The impacts of different O3 concentration on the biomass and yield of rice were studied by using OTC-1 open-top chambers. Experimental treatments included the activated charcoal-filtered air (CFA), 50 nl/L (CF50), 100 nl/L (CF100) and 200 nl/L (CF200) concentrations of O3. The O3 treatments significantly decreased the total biomass per plant. The elevated O3 exposure resulted in a more decrease in the root growth than in the shoot growth. Assessments of yield characteristics at the final harvest revealed an O3-induced decrease in the number of grains per plant, resulting from fewer ears per plant, fewer grains per ear and more unfilled grains per ear. The 1000 grain dry weight and the harvest index (HI) were not changed significantly under 50 nl/L or 100 nl/L O3 exposure, but reduced by 17.0% and 4.8% by 200 nl/L O3 treatment, respectively. Compared to the CFA treatment, CF50, CF100 and CF200 treatments caused a 8.2%, 26.1%, 49.1% decrease of the grain yield per plant, and a 14.2%, 31.7%, 51.7% decrease of the total biomass per plant, respectively. Linear regression showed that the 7 h-daily mean O3 concentration exposure for 3 months (July-September) and AOT40 (cumulative exposure accumulation over threshold 40 nl/L) were well correlated with the relative grain yield. A yield loss of 10% was estimated to be at 46.9 nl/L O3 for 7 h-daily mean O3 concentration exposure or at 12930 nl/(L.h) O3 for AOT40.